** Shares of Relay Therapeutics RLAY.O rise 7.5% to $4.76 premarket
** Co says its lead drug candidate to treat a type of locally advanced breast cancer helped patients live for about 11.4 months on average without the disease getting worse
** The drug, RLY-2608, is being tested in combination with hormone therapy
** RLAY plans to start a pivotal study testing the combination next year
** The combination was generally well tolerated in the 118 patients treated -RLAY
** Two patients discontinued treatment due to treatment-related side-effects such as nausea and loss of appetite
** Up to last close, stock down ~60% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。